LENZ Therapeutics, Inc. (NASDAQ:LENZ) Given Average Recommendation of “Buy” by Analysts

LENZ Therapeutics, Inc. (NASDAQ:LENZ) has been given a consensus rating of “Buy” by the seven ratings firms that are presently covering the firm, MarketBeat reports. Six investment analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $35.40.

Several equities research analysts recently weighed in on the company. Piper Sandler reissued an “overweight” rating and issued a $36.00 price objective on shares of LENZ Therapeutics in a report on Thursday, August 15th. HC Wainwright began coverage on LENZ Therapeutics in a research note on Monday, August 12th. They issued a “buy” rating and a $38.00 target price on the stock. William Blair raised shares of LENZ Therapeutics to a “strong-buy” rating in a report on Friday, August 30th. Finally, Raymond James initiated coverage on LENZ Therapeutics in a research note on Friday, September 27th. They issued an “outperform” rating and a $37.00 target price for the company.

Institutional Investors Weigh In On LENZ Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of LENZ. American International Group Inc. bought a new position in LENZ Therapeutics in the first quarter worth $44,000. SG Americas Securities LLC purchased a new position in LENZ Therapeutics in the 3rd quarter worth approximately $107,000. Marquette Asset Management LLC purchased a new stake in shares of LENZ Therapeutics during the first quarter valued at $131,000. Squarepoint Ops LLC bought a new stake in LENZ Therapeutics in the 2nd quarter worth about $181,000. Finally, BNP Paribas Financial Markets bought a new stake in LENZ Therapeutics in the 1st quarter worth about $362,000. Hedge funds and other institutional investors own 54.32% of the company’s stock.

LENZ Therapeutics Stock Performance

LENZ Therapeutics stock opened at $27.64 on Friday. LENZ Therapeutics has a fifty-two week low of $14.07 and a fifty-two week high of $31.00. The firm’s 50-day simple moving average is $23.83 and its 200 day simple moving average is $20.62.

LENZ Therapeutics (NASDAQ:LENZ) last posted its quarterly earnings results on Wednesday, August 14th. The company reported ($0.40) earnings per share for the quarter, beating the consensus estimate of ($0.49) by $0.09. As a group, equities analysts expect that LENZ Therapeutics will post -3.15 earnings per share for the current fiscal year.

LENZ Therapeutics Company Profile

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.